Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain

Venture capital funding into biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022.

This compares to the $7.4 billion reported across 196 deals last quarter, according to PitchBook’s Q2 2024 biopharma report.